title: Systemic delivery of adeno-associated viral vectors.
abstract: For diseases like muscular dystrophy, an effective gene therapy requires bodywide correction. Systemic viral vector delivery has been attempted since early 1990s. Yet a true success was not achieved until mid-2000 when adeno-associated virus (AAV) serotype-6, 8 and 9 were found to result in global muscle transduction in rodents following intravenous injection. The simplicity of the technique immediately attracts attention. Marvelous whole body amelioration has been achieved in rodent models of many diseases. Scale-up in large mammals also shows promising results. Importantly, the first systemic AAV-9 therapy was initiated in patients in April 2014. Recent studies have now begun to reveal molecular underpinnings of systemic AAV delivery and to engineer new AAV capsids with superior properties for systemic gene therapy.
authors.affiliation: Department of Molecular Microbiology and Immunology, School of Medicine, The University of Missouri, Columbia, MO 65212, USA; Department of Neurology, School of Medicine, The University of Missouri, Columbia, MO 65212, USA; Department of Bioengineering, The University of Missouri, Columbia, MO 65212, USA; Department of Biomedical Sciences, College of Veterinary Medicine, The University of Missouri, Columbia, MO 65212, USA. Electronic address: duand@missouri.edu.
authors.forename: Dongsheng
authors.initials: D
authors.lastname: Duan
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D002986:Clinical Trials as Topic; D000229:Dependovirus / Q000235:genetics*; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000008:administration & dosage*; D004353:Drug Evaluation, Preclinical; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage*; D006801:Humans
chemical_list: D004337:Drug Carriers